Changes in immune and glial markers in the CSF of patients with Complex Regional Pain Syndrome

Brain, Behavior, and Immunity

Volumn 21, Issue 5, 2007, Pages 668-676

  Alexander, Guillermo M ^a   Perreault, Marielle J ^a   Reichenberger, Erin R ^a   Schwartzman, Robert J ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Calcium; Cerebrospinal fluid; Chemokines; CRPS; Cytokines; GFAP; Glutamate; MCP1; Nitric oxide

Indexed keywords

BIOLOGICAL MARKER; CALCIUM; CHEMOKINE; CYTOKINE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUCOSE; GLUTAMIC ACID; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; MARKER; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUROTRANSMITTER; NITRATE; NITRIC OXIDE; NITRITE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CEREBROSPINAL FLUID; COMPLEX REGIONAL PAIN SYNDROME; CONTROLLED STUDY; FEMALE; GLIA; HUMAN; HYDROCEPHALUS; IMMUNE SYSTEM; IMMUNITY; MAJOR CLINICAL STUDY; MALE; PAIN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RADICULOPATHY; SPONDYLOLISTHESIS;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; BIOLOGICAL MARKERS; CALCIUM; CHEMOKINES; COMPLEX REGIONAL PAIN SYNDROMES; CYTOKINES; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUCOSE; GLUTAMIC ACID; HUMANS; HYDROCEPHALUS; MALE; MIDDLE AGED; NEUROGLIA; NITRATES; NITRIC OXIDE; NITRITES; PERIPHERAL NERVOUS SYSTEM DISEASES; RADICULOPATHY; SPONDYLOLISTHESIS;

EID: 34249658983     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbi.2006.10.009     Document Type: Article

References (62)

1. Abbadie C., Lindia J.A., Cumiskey A.M., Peterson L.B., Mudgett J.S., Bayne E.K., DeMartino J.A., MacIntyre D.E., and Forrest M.J. Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2. Proc. Natl. Acad. Sci. USA 100 (2003) 7947-7952
2. Abbadie C. Chemokines, chemokine receptors and pain. Trends Immunol. 26 (2005) 529-534
3. Alexander G.M., van Rijn M.A., van Hilten J.J., Perreault M.J., and Schwartzman RJ. Changes in cerebrospinal fluid levels of pro-inflammatory cytokines in CRPS. Pain 116 (2005) 213-219
4. Anderson R.E., Winnerkvist A., Hansson L.O., Nilsson O., Rosengren L., Settergren G., and Vaage J. Biochemical markers of cerebrospinal ischemia after repair of aneurysms of the descending and thoracoabdominal aorta. J. Cardiothorac. Vasc. Anesth. 17 (2003) 598-603
5. Babcock A.A., Kuziel W.A., Rivest S., and Owens T. Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS. J. Neurosci. 23 (2003) 7922-7930
6. Bartosik-Psujek H., and Stelmasiak Z. Correlations between IL-4, IL-12 levels and CCL2, CCL5 levels in serum and cerebrospinal fluid of multiple sclerosis patients. J. Neural. Transm. 112 (2005) 797-803
7. Blum-Degen D., Muller T., Kuhn W., Gerlach M., Przuntek H., and Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci. Lett. 202 (1995) 17-20
8. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
9. Correll G.E., Maleki J., Gracely E.J., Muir J.J., and Harbut R.E. Subanesthetic ketamine infusion therapy: a retrospective analysis of a novel therapeutic approach to complex regional pain syndrome. Pain Med. 5 (2004) 263-275
10. DeLeo J.A., and Yezierski R.P. The role of neuroinflammation and neuroimmune activation in persistent pain. Pain 90 (2001) 1-6
11. Fishman R.A. Cerebrospinal Fluid in Diseases of the Nervous System. second ed. (1992), W.B. Saunders Company, Philadelphia, Pennsylvania, USA pp. 197-222
12. Goldberg M.E., Domsky R., Scaringe D., Hirsh R., Dotson J., Sharaf I., Torjman M.C., and Schwartzman R.J. Multi-day low dose ketamine infusion for the treatment of complex regional pain syndrome. Pain Physician. 8 (2005) 175-179
13. Harden N.R., and Bruehl S. Diagnostic criteria: the statistical derivation of the four criterion factors. In: Wilson P.R., Stanton-Hicks M.D., and Harden R.N. (Eds). CRPS: Current Diagnosis and Therapy (2005), IASP Press, Seattle, WA, USA 45-58
14. Hardingham N.R., Bannister N.J., Read J.C., Fox K.D., Hardingham G.E., and Jack J.J. Extracellular calcium regulates postsynaptic efficacy through group 1 metabotropic glutamate receptors. J. Neurosci. 26 (2006) 6337-6345
15. Hashimoto A., Nishikawa T., Oka T., Takahashi K., and Hayashi T. Determination of free amino acid enantiomers in rat brain and serum by high-performance liquid chromatography after derivatization with N-tert-butyloxycarbonyl-l-cysteine and o-phthaldialdehyde. J. Chromatogr. 582 (1992) 41-48
16. Hulshof S., Montagne L., De Groot C.J., and Van Der Valk P. Cellular localization and expression patterns of interleukin-10, interleukin-4, and their receptors in multiple sclerosis lesions. Glia 38 (2002) 24-35
17. Hunt S.P., and Mantyh P.W. The molecular dynamics of pain control nature reviews. Neuroscience 2 (2001) 83-91
18. Ikeda H., Stark J., Fischer H., Wagner M., Drdla R., Jager T., and Sandkuhler J. Synaptic amplifier of inflammatory pain in the spinal dorsal horn. Science 312 (2006) 1659-1662
19. Inoue K. The function of microglia through purinergic receptors: neuropathic pain and cytokine release. Pharmacol. Ther. 109 (2006) 210-226
20. Janig W., and Baron R. Complex regional pain syndrome: mystery explained?. Lancet Neurol. 2 (2003) 687-697
21. Joborn C., Hetta J., Niklasson F., Rastad J., Wide L., Agren H., Akerstrom G., and Ljunghall S. Cerebrospinal fluid calcium, parathyroid hormone, and monoamine and purine metabolites and the blood-brain barrier function in primary hyperparathyroidism. Psychoneuroendocrinology 16 (1991) 311-322
22. Klein M.A., Moller J.C., Jones L.L., Bluethmann H., Kreutzberg G.W., and Raivich G. Impaired neuroglial activation in interleukin-6 deficient mice. Glia 19 (1997) 227-233
23. Koeberle P.D., Gauldie J., and Ball A.K. Effects of adenoviral-mediated gene transfer of interleukin-10, interleukin-4, and transforming growth factor-beta on the survival of axotomized retinal ganglion cells. Neuroscience 125 (2004) 903-920
24. Kotani N., Kushikata T., Hashimoto H., Kimura F., Muraoka M., Yodono M., Asai M., and Matsuki A. Intrathecal methylprednisolone for intractable postherpetic neuralgia. N. Engl. J. Med. 343 (2000) 1514-1519
25. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 19 (1996) 312-318
26. Larson A.A., Giovengo S.L., Russell I.J., and Michalek J.E. Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways. Pain 87 (2000) 201-211
27. Lehtimaki K.A., Keranen T., Huhtala H., Hurme M., Ollikainen J., Honkaniemi J., Palmio J., and Peltola J. Regulation of IL-6 system in cerebrospinal fluid and serum compartments by seizures: the effect of seizure type and duration. J. Neuroimmunol. 152 (2004) 121-125
28. Marchand F., Perretti M., and McMahon S.B. Role of the immune system in chronic pain. Nat. Rev. Neurosci. 6 (2005) 521-532
29. McMahon S.B., Cafferty W.B., and Marchand F. Immune and glial cell factors as pain mediators and modulators. Exp. Neurol. 192 (2005) 444-462
30. Meller S.T., and Gebhart G.F. Nitric oxide (NO) and nociceptive processing in the spinal cord. Pain 52 (1993) 127-136
31. Nakajima K., and Kohsaka S. Microglia: activation and their significance in the central nervous system. J. Biochem. (Tokyo) 130 (2001) 169-172
32. Natelson B.H., Weaver S.A., Tseng C.L., and Ottenweller J.E. Spinal fluid abnormalities in patients with chronic fatigue syndrome. Clin. Diagn. Lab. Immunol. 12 (2005) 52-55
33. Nishiyori A., Minami M., Ohtani Y., Takami S., Yamamoto J., Kawaguchi N., Kume T., Akaike A., and Satoh M. Localization of fractalkine and CX3CR1 mRNAs in rat brain: does fractalkine play a role in signaling from neuron to microglia?. FEBS Lett. 429 (1998) 167-172
34. Norgren N., Sundstrom P., Svenningsson A., Rosengren L., Stigbrand T., and Gunnarsson M. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology 63 (2004) 1586-1590
35. Park K.W., Lee D.Y., Joe E.H., Kim S.U., and Jin B.K. Neuroprotective role of microglia expressing interleukin-4. J. Neurosci. Res. 81 (2005) 397-402
36. Peres M.F., Zukerman E., Senne Soares C.A., Alonso E.O., Santos B.F., and Faulhaber M.H. Cerebrospinal fluid glutamate levels in chronic migraine. Cephalalgia 24 (2004) 735-739
37. Rajkumar S.V., Fonseca R., and Witzig T.E. Complete resolution of reflex sympathetic dystrophy with thalidomide treatment. Arch. Intern. Med. 161 (2001) 2502-2503
38. Rosengren L.E., Wikkelso C., and Hagberg L. A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adults. J. Neurosci. Methods. 51 (1994) 197-204
39. Rota E., Bellone G., Rocca P., Bergamasco B., Emanuelli G., and Ferrero P. Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients. Neurol. Sci. 27 (2006) 33-39
40. Schwartzman R.J., Grothusen J., Kiefer T.R., and Rohr P. Neuropathic central pain: epidemiology, etiology, and treatment options. Arch. Neurol. 58 (2001) 1547-1550
41. Schwartzman R.J., Chevlen E., and Bengtson K. Thalidomide has activity in treating complex regional pain syndrome. Arch. Intern. Med. 163 (2003) 1487-1488
42. Schwartzman, R.J., Irving, G., Wallace, M., et al., 2005. A multicenter, open label, 12 week study with extension to evaluate the safety and efficacy of Lenalidomide (CC5013) in the treatment of Complex Regional Pain Syndrome type-I. Abstract: 11th World Congress on Pain. Seattle, IASP Press, p. 580.
43. Spreux-Varoquaux O., Bensimon G., Lacomblez L., Salachas F., Pradat P.F., Le Forestier N., Marouan A., Dib M., and Meininger V. Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J. Neurol. Sci. 193 (2002) 73-78
44. Steensberg A., Dalsgaard M.K., Secher N.H., and Pedersen B.K. Cerebrospinal fluid IL-6, HSP72, and TNF-alpha in exercising humans. Brain Behav. Immun. 20 (2006) 585-589
45. Stoeck K., Bodemer M., Ciesielczyk B., Meissner B., Bartl M., Heinemann U., and Zerr I. Interleukin 4 and interleukin 10 levels are elevated in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Arch. Neurol. 62 (2005) 1591-1594
46. Svensson C.I., Marsala M., Westerlund A., Calcutt N.A., Campana W.M., Freshwater J.D., Catalano R., Feng Y., Protter A.A., Scott B., and Yaksh T.L. Activation of p38 mitogen-activated protein kinase in spinal microglia is a critical link in inflammation-induced spinal pain processing. J. Neurochem. 86 (2003) 1534-1544
47. Toda K., Muneshige H., and Asou T. Intravenous regional block with lidocaine for treatment of complex regional pain syndrome. Clin. J. Pain 22 (2006) 222-224
48. Tsuda M., Inoue K., and Salter M.W. Neuropathic pain and spinal microglia: a big problem from molecules in "small" glia. Trends Neurosci. 28 (2005) 101-107
49. Verboon-Maciolek M.A., Thijsen S.F., Hemels M.A., Menses M., van Loon A.M., Krediet T.G., Gerards L.J., Fleer A., Voorbij H.A., and Rijkers G.T. Inflammatory mediators for the diagnosis and treatment of sepsis in early infancy. Pediatr. Res. 59 (2006) 457-461
50. Wallace M.S., Ridgeway B.M., Leung A.Y., Gerayli A., and Yaksh T.L. Concentration-effect relationship of intravenous lidocaine on the allodynia of complex regional pain syndrome types I and II. Anesthesiology 92 (2000) 75-83
51. Watkins L.R., and Maier S.F. The pain of being sick: implications of immune-to-brain communication for understanding pain. Annu. Rev. Psychol. 51 (2000) 29-57
52. Watkins L.R., Milligan E.D., and Maier S.F. Glial activation: a driving force for pathologic pain. Trends Neurosci. 24 (2001) 450-455
53. Watkins L.R., and Maier S.F. Glia: a novel drug discovery target for clinical pain. Nat. Rev. Drug Discov. 2 (2003) 973-985
54. Watkins L.R., and Maier S.F. Immune regulation of central nervous system functions: from sickness responses to pathological pain. J. Intern. Med. 257 (2005) 139-155
55. Waxman S.G., Dib-Hajj S., Cummins T.R., and Black J.A. Sodium channels and pain. Proc. Natl. Acad. Sci. USA 96 (1999) 7635-7639
56. Wieseler-Frank J., Maier S.F., and Watkins L.R. Glial activation and pathological pain. Neurochem. Int. 45 (2004) 389-395
57. Willis W.D. Role of neurotransmitters in sensitization of pain responses. Ann. N. Y. Acad. Sci. 933 (2001) 142-156
58. Wilms H., Sievers J., Dengler R., Bufler J., Deuschl G., and Lucius R. Intrathecal synthesis of monocyte chemoattractant protein-1 (MCP-1) in amyotrophic lateral sclerosis: further evidence for microglial activation in neurodegeneration. J. Neuroimmunol. 144 (2003) 139-142
59. Woolf C.J., and Salter M.W. Neuronal plasticity: increasing the gain in pain. Science. 288 (2000) 1765-1769
60. Yamada K., Nishiwaki K., Hattori K., Senzaki K., Nagata M., Komatsu T., Shimada Y., and Nabeshima T. No changes in cerebrospinal fluid levels of nitrite, nitrate and cyclic GMP with aging. J. Neural. Transm. 104 (1997) 825-831
61. Yumite Y., Takeuchi K., Harada Y., Ogawa N., and Inoue H. Concentration of nitric oxide (NO) in spinal fluid of chronic spinal disease. Acta Med. Okayama. 55 (2001) 219-228
62. Zhang J., and De Koninck Y. Spatial and temporal relationship between monocyte chemoattractant protein-1 expression and spinal glial activation following peripheral nerve injury. J. Neurochem. 97 (2006) 772-783